Holen Sie sich die Stockscreener-App
6.19
1.81%
0.11
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.08
Offen:
$6.08
24-Stunden-Volumen:
856.92K
Relative Volume:
0.81
Marktkapitalisierung:
$482.26M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-2.0362
EPS:
-3.04
Netto-Cashflow:
$-91.73M
1W Leistung:
-5.06%
1M Leistung:
+19.96%
6M Leistung:
-7.34%
1J Leistung:
+57.11%
1-Tages-Spanne:
$6.06
$6.39
1-Wochen-Bereich:
$5.71
$7.33
52-Wochen-Spanne:
$2.41
$7.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.19 | 473.69M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Eingeleitet | Needham | Buy |
| 2025-06-26 | Eingeleitet | Citigroup | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
What analysts say about Solid Biosciences Inc. stockQuarterly Investment Review & Growth-Oriented Investment Plans - mfd.ru
Solid Biosciences (SLDB) Gets a Buy from Wedbush - The Globe and Mail
Citizens reiterates Market Outperform rating on Solid Biosciences stock By Investing.com - Investing.com Nigeria
Citizens reiterates Market Outperform rating on Solid Biosciences stock - Investing.com
Solid Biosciences advances Duchenne treatment with FDA alignment By Investing.com - Investing.com South Africa
Solid Biosciences: Positive FDA Meeting SGT-003 Sets Up Next Milestones (NASDAQ:SLDB) - Seeking Alpha
Needham Reiterates Buy Rating for Solid Biosciences (SLDB) at $1 - GuruFocus
Needham & Company LLC Reaffirms Buy Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences (SLDB) Gains FDA Alignment for Duchenne Trial - GuruFocus
Solid Biosciences Receives Positive FDA Feedback - Intellectia AI
Solid Biosciences To Dose First Patient In IMPACT DUCHENNE Phase 3 Trial In Q1'26 - Nasdaq
Solid Biosciences stock rises after FDA alignment on Phase 3 trial design - Investing.com Australia
Solid Biosciences (SLDB) Advances Duchenne Therapy with FDA Support - GuruFocus
Solid Biosciences Aligns With FDA on Phase 3 Trial Design for Duchenne Muscular Dystrophy Gene Therapy - marketscreener.com
Solid Bio, FDA agree on trial for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences advances Duchenne treatment with FDA alignment - Investing.com
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy - The Manila Times
Merger Talk: Why is Solid Biosciences Inc. stock going upWeekly Stock Analysis & Safe Entry Point Identification - baoquankhu1.vn
Death Cross: What are Solid Biosciences Incs earnings expectations2025 Trade Ideas & Fast Entry Momentum Alerts - baoquankhu1.vn
Solid Biosciences CTO Herzich sells $70k in SLDB stock By Investing.com - Investing.com Canada
Solid Biosciences chief regulatory officer sells $79,544 in SLDB By Investing.com - Investing.com UK
Solid Biosciences CMO Brooks sells $81k in shares By Investing.com - Investing.com South Africa
Solid Biosciences chief regulatory officer sells $79,544 in SLDB - Investing.com India
Solid Biosciences CTO Herzich sells $70k in SLDB stock - Investing.com
Solid Biosciences CEO Cumbo sells $315,092 in stock By Investing.com - Investing.com Canada
Ilan Ganot, Solid Biosciences director, sells $46k in shares By Investing.com - Investing.com UK
Solid Biosciences CEO Cumbo sells $315,092 in stock - Investing.com Nigeria
Ilan Ganot, Solid Biosciences director, sells $46k in shares - Investing.com
Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 14,783 Shares - MarketBeat
Solid Biosciences (NASDAQ:SLDB) CTO Sells $70,228.20 in Stock - MarketBeat
Solid Biosciences Flies Ahead of Summit - Baystreet.ca
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells 48,913 Shares of Stock - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Sees Large Decline in Short Interest - MarketBeat
Solid Biosciences CFO sells $172k in shares By Investing.com - Investing.com UK
Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 26,837 Shares - MarketBeat
Alexander Cumbo Sells 80,258 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Gabriel Brooks Sells 28,335 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Solid Biosciences (NASDAQ:SLDB) COO Sells $243,245.24 in Stock - MarketBeat
Solid Biosciences COO Howton sells $243k in shares By Investing.com - Investing.com Australia
Paul Herzich Sells 26,250 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Solid Biosciences CFO sells $172k in shares - Investing.com
Solid Biosciences COO Howton sells $243k in shares - Investing.com
Insider Selling: Solid Biosciences (NASDAQ:SLDB) Insider Sells 26,535 Shares of Stock - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Solid Biosciences Inc-Aktie (SLDB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cumbo Alexander | President and CEO |
Feb 04 '26 |
Sale |
6.44 |
48,913 |
315,093 |
222,018 |
| Ganot Ilan | Director |
Feb 04 '26 |
Sale |
6.44 |
7,205 |
46,414 |
25,271 |
| Tan Kevin | CFO & Treasurer |
Feb 04 '26 |
Sale |
6.44 |
14,783 |
95,231 |
94,201 |
| Brooks Gabriel | Chief Medical Officer |
Feb 04 '26 |
Sale |
6.44 |
12,616 |
81,271 |
84,092 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 04 '26 |
Sale |
6.44 |
12,348 |
79,545 |
70,327 |
| Herzich Paul | Chief Technology Officer |
Feb 04 '26 |
Sale |
6.44 |
10,905 |
70,249 |
69,067 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):